Who are Ramosetron, Aprepitant, Dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ondansetron, dexamethasone, aprepitant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ramosetron-aprepitant-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ramosetron, Aprepitant, Dexamethasone — Competitive Intelligence Brief

Ramosetron, Aprepitant, Dexamethasone (Ramosetron, Aprepitant, Dexamethasone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 antagonist / NK1 antagonist / corticosteroid combination. Area: Oncology / Supportive Care.

marketed 5-HT3 antagonist / NK1 antagonist / corticosteroid combination 5-HT3 receptor, NK1 receptor, glucocorticoid receptor Oncology / Supportive Care Small molecule Live · refreshed every 30 min

Target snapshot

Ramosetron, Aprepitant, Dexamethasone (Ramosetron, Aprepitant, Dexamethasone) — Hallym University Medical Center. This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different mechanisms: 5-HT3 antagonism, NK1 antagonism, and corticosteroid action.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ramosetron, Aprepitant, Dexamethasone TARGET	Ramosetron, Aprepitant, Dexamethasone	Hallym University Medical Center	marketed	5-HT3 antagonist / NK1 antagonist / corticosteroid combination	5-HT3 receptor, NK1 receptor, glucocorticoid receptor
Ondansetron, dexamethasone, aprepitant	Ondansetron, dexamethasone, aprepitant	University of Oklahoma	phase 3	Antiemetic combination (5-HT3 antagonist, NK1 antagonist, corticosteroid)	5-HT3 receptor, NK1 receptor, glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 antagonist / NK1 antagonist / corticosteroid combination class)

Hallym University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ramosetron, Aprepitant, Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/ramosetron-aprepitant-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab